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Key Points
• Function and maturation of
myeloid DCs is abnormal in
AP-3 complex-deficient
patients.
• IFN-a secretion in response
to HSV-1 is reduced in
AP-3–deficient patients.
Hermansky-Pudlak syndrome type 2 (HPS2) is a primary immunodeficiency due to
adaptor protein-3 (AP-3) complex deficiency. HPS2 patients present neutropenia, partial
albinism, and impaired lysosomal vesicles formation in hematopoietic cells. Given the
role of dendritic cells (DCs) in the immune response, we studied monocyte-derived DCs
(moDCs) and plasmacytoid DCs (pDCs) in two HPS2 siblings. Mature HPS2 moDCs
showed impaired expression of CD83 and DC–lysosome-associated membrane protein
(LAMP), low levels of MIP1-b/CCL4, MIG/CXCL9, and severe defect of interleukin-12
(IL-12) secretion. DCs in lymph-node biopsies from the same patients showed a diffuse
cytoplasmreactivity in a large fractionofDC-LAMP1 cells, insteadof the classical dot-like
stain. In addition, analysis of pDC-related functions of blood-circulating mononuclear
cells revealed reduced interferon-a secretion in response to herpes simplex virus-1 (HSV-1), whereas granzyme-B induction upon
IL-3/IL-10 stimulationwas normal. Finally, T-cell costimulatory activity, asmeasured bymixed lymphocyte reaction assay, was lower
in patients, suggesting that function and maturation of DCs is abnormal in patients with HPS2. (Blood. 2016;127(26):3382-3386)
Introduction
Hermansky-Pudlak syndrome type 2 (HPS2) is an autosomal recessive
disease caused by mutations of the AP3B1 gene, encoding for the
beta3A subunit of the heterotetrameric adaptor protein-3 complex. The
adaptor protein-3 (AP-3) complex is involved in protein sorting and in
cargo selective transport of proteins from endosomes to the lysosome.
All HPS2 patients described to date are homozygous or compound
heterozygous for mutations in the AP3B1 gene, resulting in the com-
plete absence of beta3A expression.1-4
HPS2 patients display recurrent viral and bacterial infections due to
defects of cytotoxic T cells, natural killer cells,5,6 and CD1-dependent
antigen presentation.7,8 Neutrophils are also involved, but neutropenia
that is observed in allHPS2patients is usually responsive to granulocyte
colony-stimulating factor (CSF) treatment, suggesting that the neutro-
phil abnormalities do not account for the susceptibility to infections.9
There is evidence that AP-3 is involved in toll-like receptor (TLR)
signaling and major histocompatibility complex functions of murine
dendritic cells (DCs).10 In addition, AP-3 is essential for TLR7- and
TLR9-dependent secretion of type I interferon (IFN) by plasmacytoid
DCs (pDCs).11,12 These studies suggest that DCs might play a role in
the pathogenesis of infections in HPS2.
Therefore, we studied the maturation of monocyte-derived DCs
(moDCs) in two siblings with HPS213 by analysis of CD83 and
DC–lysosome-associated membrane protein (DC-LAMP) expression,
and cytokine secretion. We also observed a low percentage of cir-
culating myeloid DCs (mDCs) and pDCs. Moreover, following in
vitro stimulation, peripheral bloodmononuclear cells (PBMCs)were
unable to secrete IFN-a uponherpes simplex virus-1 (HSV-1) infection.
Finally, analysis of the costimulatory activity ofmDCs for lymphocytes
showed that DCs from AP-3–deficient patients display delayed
maturation and abnormal cytokine secretion.
Study design
Monocytes were differentiated into DCs by the addition of granulocyte-
macrophage CSF (GM-CSF) 50 ng/mL and 20 ng/mL interleukin-4 (IL-4)
(PeproTech).After6daysof culture, analysisofhuman leukocyteantigen–antigen
Drelated (HLA-DR) showed that at least 80%of cellswereCD1a1/CD142. Final
maturation was induced by stimulation with 100 ng/mL lipopolysaccharide
(LPS) (Sigma-Aldrich), 500U/mL IFN-g (R&DSystems), orwithmultimeric
soluble human CD40 ligand at 1 mg/mL (CD40L; Miltenyi Biotec, Bergisch
Gladbach, Germany) for an additional 24 or 48 hours.
In immunofluorescence studies, cellswere seeded onglass slides by cytospin
and permeabilized with 100% ice-cold methanol. Immunohistochemistry (IHC)
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studies were performed on formalin-fixed paraffin-embedded sections obtained
from nodular lymphocyte predominant Hodgkin lymphoma biopsies.
More details of experimental procedures, materials, and analysis are pro-
vided in supplemental Materials and Methods, available on the BloodWeb site.
Results and discussion
Impaired maturation of moDCs in HPS2 patients
In order to studyDCs inHPS2 patients, we cultured adherence-purified
monocytes with IL-4 and GM-CSF, and added LPS to cultures to
induce full maturation of DCs. We evaluated moDCs maturation by
immunostaining with anti–DC-LAMP, anti–HLA-DR, and anti-CD83
moAbs. After 24 hours stimulation, DC-LAMP expression by HPS2
moDCs was lower in comparison with cells derived from healthy
subjects (Figure1A).Likewise, the analysis ofCD83expression inDCs
of HPS2 patients revealed a striking difference of CD83 staining,
suggesting that DCs from HPS2 patients have a defect of cell
maturation (Figure 1A).However, after 48 hours of culture,DC-LAMP
became detectable (supplemental Figure 1). CD83 expression was
detectablewith a 0.9- and 1.4-fold increase, respectively, in the 2HPS2
patients as compared with a fivefold upregulation in control moDCs.
DC activation by the use of solublemultimericCD40-ligand resulted in
a1.6- and2.2-fold increaseofCD83 in the2HPS2patients as compared
with a 5.5-fold upregulation in control moDCs. These results suggest
that DCs in HPS2 patients have a delay in DC activation rather than a
complete defect in maturation.
Because both patients underwent lymph node biopsy for lympho-
proliferative disease, we explored DC-LAMP expression in the context
ofHPS2-associatedHodgkin lymphoma.We could detectDC-LAMP1
cells in the extranodular non-neoplastic T-cell area of both patients and
controls (Figure 1B). Remarkably, the subcellular distribution of DC-
LAMP in patients’ tissue was abnormal in a large fraction of positive
cells, consisting of a diffuse reactivity in the cytoplasm instead of the
classical dot-like, paranuclearGolgi stain (Figure 1B, insert). By double
IHC, numerous DC-LAMP1 cells coexpressed S100 (62%), Langerin
(45%), and CD1a (41%) (Figure 1C) with no immunoreactivity with
anti-CD123, -CD163, and -CD14moAbs (not shown), thus suggesting
a Langerhans-derived interdigitating DC identity for many of them.
Altered cytokine production by mature moDCs and pDCs of
HPS2 patients
Because DCs are the main producers of cytokines that regulate T-cell
activation, we decided to evaluate chemokine and cytokine production
bymoDCs after culture for 24 hourswithLPS. StimulatedDCs showed
a defective production of MIP1-b/CCL4 and MIG/CXCL9, two
chemokines that inducemigration of activated T cells, normal secretion
of IL-23, reduced TNF-a levels, and a complete defect in IL-12
production (Figure 2A). This result is consistent with those obtained in
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Figure 1. Altered expression of maturation markers
in HPS2 DCs. (A) moDCs from HPS2 patients and
control were induced to mature by culture with LPS for
24 hours, seeded on glass, and permeabilized with
methanol. DCs were stained with moAbs against DC-
LAMP (red) or HLA-DR (green) (top panels), and with
anti-CD83 (green) and DAPI (blue) (bottom panels).
Images were acquired using a confocal microscope
(LSM 510 META; Carl Zeiss Inc.) with a 3100/1.3 oil
objective. Images were acquired sequentially using
separate laser excitations to avoid crosstalk between
the fluorophore signals. (B-C) IHC on formalin-fixed
paraffin-embedded sections obtained from lymph nodes
of Pt1, Pt2, and control. In the lymph nodes from HPS2-
patients, DC-LAMP reactivity is diffused in the cytoplasm,
whereas in control, DC-LAMP reactivity is limited to the
classical paranuclear dot (B, inserts). By double IHC (C),
DC-LAMP1 cells (brown) coexpress CD1a (41% of DC-
LAMP1 cells), Langerin (45%), and S100 protein (62%)
(blue). CTR, control; DAPI, 49,6-diamidino-2-phenylindole;
MHC, major histocompatibility complex; Pt, patient.
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pearlmice.10 Given the defect of IL-12 production byHPS2moDCs, it
is likely that T cells of HPS2 patientsmight display impaired T helper 1
polarization.10Because IFN-g has the unique capacity to primeDCs for
high IL-12production,we investigated theeffectof this cytokineon IL-12
secretion.14,15 Results reported in supplemental Figure 2A show that the
combined stimulation with LPS and IFN-g was able to restore IL-12
secretion to normal levels, suggesting that under optimal conditions of
stimulation, IL-12 production is restored. In addition, the secretion
by mature moDCs of other cytokines and chemokines, such as MIP1-
a/CCL3, granulocyte-CSF, and IL-6 was normal, except for an evident
overproduction of MCP-1/CCL2 and IL-8/CXCL8 by HPS2 immature
DCs (supplemental Figure 2B). Higher production of MCP-1/CCL2 and
IL-8/CXCL8 by HPS2 DCs in the absence of stimulation might reflect
the constitutive activation of pro-inflammatory pathways in these cells.
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Figure 2. Impairment of DC functions in HPS2 patients. DCs were generated from freshly isolated monocytes by adding IL-4 and GM-CSF for 6 days. Final maturation has
been induced after the addition of LPS for another 24 hours. Analysis of MIP1-b/CCL4, MIG/CXCL9, IL-12, TNF-a, and IL-23 production (A, all panels) by immature DCs (gray
bars) and mature DCs (black bars) derived from HPS2 patients or from a healthy subject. Statistical analysis by non-parametric test shows a significant difference (*P , .05). (B)
mDCs (s) and pDCs (♢) were evaluated by FACS analysis in peripheral blood from the HPS2 patients (d and ♦) as compared with the percentages detected in healthy
subjects of comparable age (s and ♢). Statistical analysis of DC counts shows that mDCs and pDCs were significantly lower in HPS2 patients after 2 independent
measurements as compared with cell counts in 24 normal control subjects (**P , .005; ***P , .001). (C) IFN-a production, measured in triplicate, by freshly isolated PBMCs
after stimulation for 24 hours with 6 mg/mL CpG, HSV-1 (copies/200 mL), or medium alone in HPS2 and 1 control subject. Statistical analysis by non-parametric test shows a
significant difference (*P , .05). This experiment is representative of 2 experiments performed. (D) PBMCs were stimulated with 6 mg/mL CpG for 5 hours in the presence of
brefeldin A for the last 3 hours. At the end of stimulation, PBMCs were stained with anti–BDCA2-FITC Ab and anti–CD123-Vioblue Ab to identify pDCs, and with an anti-
IFNa–antigen-presenting cell Ab. The graph shows the percentage (gray bars) and (MFI, black bars) of IFN-a–positive cells. (E) PBMCs were stimulated with 6 mg/mL CpG
for 5 hours. At the end of incubation, PBMCs were collected and IFN-a levels were evaluated by real-time polymerase chain reaction. Levels of HPRT messenger RNA were
used for normalization. (F) MLR was performed by evaluation of the percentage of proliferating CD31 cells after incubation with irradiated PBMCs from HPS2 patients or a
control subject for 7 days. Statistical analysis by non-parametric test shows a significant difference (*P , .05). Ab, antibody; CTR, control; HPRT, hypoxanthine guanine
phosphoribosyltransferase; MFI, mean fluorescence intensity; Pt, patient.
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The abnormal pattern of IL-8/CXCL8 secretion may contribute to
the altered neutrophil homeostasis observed in HPS2 patients.
Flow cytometric analysis revealed a decreased percentage of
circulating mDCs and pDCs, suggesting an abnormal trafficking of
DCs from draining tissues to lymphoid organs and blood circulation
(Figure 2B). Interestingly, analysis of blood cell counts in pearlmice
has shown that the number of conventional DC and pDC is normal.16
Likewise, pearl mice are not neutropenic and do not have cyclic
neutropenia, two events observed in HPS2 patients and canine cyclic
hematopoiesis in dogs, respectively.17 Altogether, these observations
highlight differences between HSP2 patients and the pearl mouse
model. pDCs functions in AP-3–deficient patients were investigated in
terms of IFN-a secretion in response to HSV-1 and cytosine guanine
dinucleotide (CpG) stimulation (a TLR9 agonist). Because pDCs are
the main IFN-a producers among hematopoietic cells,12,18 freshly
isolated PBMCs were stimulated with serial dilutions of vital HSV-1
or CpG, and IFN-a levels evaluated after 24 hours. Surprisingly,
supernatants from PBMCs obtained from HPS2 patients showed a
complete lack of IFN-a production in comparison with the abundant
levels detectedwith control cells (Figure 2C). To further investigate the
impairment of IFN-a production inHPS2 pDCs, the expression of IFN-a
was investigated following stimulation with CpG. Analysis of IFN-a
protein production by intracellular fluorescence-activated cell sorter
(FACS) analysis revealed a comparable number of IFN-a–producing
cells in cells from HPS2 patients and control subjects. However, the
strong reduction in the mean fluorescence intensity indicated that the
degree of IFN-a production was strongly reduced in HPS2 patients
(Figure 2D). The defective production of IFN-a in HPS2 patients was
also confirmed at the messenger RNA level by real-time polymerase
chain reaction (Figure 2E). Taking together, these results suggest that
both the reduced number of circulating pDCs and the reduced ability to
release IFN-a may concur to determine the impairment of IFN-a
secretion by PBMCs from HPS2 patients. In contrast, granzyme B
production upon IL-3/IL-10 stimulation, evaluated both in the cell
supernatants and by intracellular staining, was normal (supplemental
Figure 3). These results suggest that the AP-3 complex may play a
specific, nonredundant role in TLR7 and TLR9 activation pathways of
pDCs. This is in accord with previous observations11,12 and with the
finding that pDCs frompearlmice fail to secrete type I IFNaftermurine
cytomegalovirus infection in vitro.16
DCs of HPS2 patients display a reduced ability to induce
T-cell proliferation
The antigen-presenting functions ofDCswas investigated by analyzing
the ability of freshly isolated irradiated PBMCs to induce proliferation
of allogeneic normal T cells in the mixed lymphocyte reaction (MLR)
assay.19,20 Analysis of proliferation of the responder T cells was
evaluated by carboxyfluorescein diacetate succinimidyl ester staining.
A significant proliferative response of T cells was observed with cells
obtained from both HPS2 patients and the control subjects. However,
the percentage of T cells that have entered the cell cycle after 7 days
of culture was significantly lower when PBMCs from HPS2 patients
were used to induce the T-cell response (Figure 2F; supplemental
Figure 4). At the moment, it is unclear whether HPS2 DCs have a
defective ability to induce T-cell proliferation or whether the reduced
number of DCs present in the PBMCs obtained from HPS2 patients
might be responsible for the reducedT-cell proliferation observed in the
MLR assay.
Taken together, these observations suggest that AP-3 deficiency
results in abnormalmaturation of monocyte-derivedDCs and impaired
total antigen-presenting cell activity, as measured by MLR assay.
Overall, we propose that the impairment of DC activity in HPS2
patients contributes to susceptibility to bacterial and viral infections
observed in these patients.
Acknowledgments
The authors thankMarco Cassatella and his group, and in particular,
Nicola Tamassia for IFN-a analysis.
This work was supported by grants from the European Union
(FP7HLH-cure, project #201461) and Progetti di Rilevante Interesse
Nazionale (PRIN) 2009 (R.B.).
Authorship
Contribution: A. Prandini and V.S. codesigned and reviewed the
study, and performed cellular studies and FACS analysis; F.C. set up
immunocytology studies; D.M. performed FACS analysis; M.A.D.F.
provided theherpesvirus andperformedviral studies;A.Plebani,L.D.N.,
and F.P. obtained clinical information; W.V., L.L., and F.F. performed
immune-histopathology studies; S.S. made substantial contributions to
interpretation of the data; and R.B. supervised the project and helped to
write the manuscript.
Conflict-of-interest disclosure: The authors declare no competing
financial interests.
Correspondence:RaffaeleBadolato, InstituteofMolecularMedicine
“Angelo Nocivelli,” University of Brescia, c/o Spedali Civili, 25123
Brescia, Italy; e-mail: raffaele.badolato@unibs.it.
References
1. Badolato R, Parolini S. Novel insights from
adaptor protein 3 complex deficiency. J Allergy
Clin Immunol. 2007;120(4):735-741, quiz
742-743.
2. Jessen B, Bode SFN, Ammann S, et al. The
risk of hemophagocytic lymphohistiocytosis in
Hermansky-Pudlak syndrome type 2. Blood.
2013;121(15):2943-2951.
3. Dell’Angelica EC. AP-3-dependent trafficking and
disease: the first decade. Curr Opin Cell Biol.
2009;21(4):552-559.
4. Dotta L, Parolini S, Prandini A, et al.
Clinical, laboratory and molecular signs of
immunodeficiency in patients with partial oculo-
cutaneous albinism. Orphanet J Rare Dis. 2013;
8(1):168.
5. Clark RH, Stinchcombe JC, Day A, et al. Adaptor
protein 3-dependent microtubule-mediated
movement of lytic granules to the immunological
synapse. Nat Immunol. 2003;4(11):1111-1120.
6. Fontana S, Parolini S, Vermi W, et al. Innate
immunity defects in Hermansky-Pudlak type 2
syndrome. Blood. 2006;107(12):4857-4864.
7. Briken V, Jackman RM, Dasgupta S, Hoening S,
Porcelli SA. Intracellular trafficking pathway of
newly synthesized CD1b molecules. EMBO J.
2002;21(4):825-834.
8. Sugita M, Cao X, Watts GFM, Rogers RA,
Bonifacino JS, Brenner MB. Failure of trafficking
and antigen presentation by CD1 in AP-3-deficient
cells. Immunity. 2002;16(5):697-706.
9. Wenham M, Grieve S, Cummins M, et al. Two
patients with Hermansky Pudlak syndrome type
2 and novel mutations in AP3B1. Haematologica.
2010;95(2):333-337.
10. Mantegazza AR, Guttentag SH, El-Benna J, et al.
Adaptor protein-3 in dendritic cells facilitates
phagosomal toll-like receptor signaling and
antigen presentation to CD4(1) T cells. Immunity.
2012;36(5):782-794.
11. Sasai M, Linehan MM, Iwasaki A. Bifurcation of
toll-like receptor 9 signaling by adaptor protein 3.
Science. 2010;329(5998):1530-1534.
12. Blasius AL, Arnold CN, Georgel P, et al. Slc15a4,
AP-3, and Hermansky-Pudlak syndrome proteins
are required for toll-like receptor signaling in
BLOOD, 30 JUNE 2016 x VOLUME 127, NUMBER 26 IMPAIRMENT OF DCs IN AP-3 COMPLEX DEFICIENCY PATIENTS 3385
For personal use only.on August 7, 2016. by guest  www.bloodjournal.orgFrom 
plasmacytoid dendritic cells. Proc Natl Acad Sci
USA. 2010;107(46):19973-19978.
13. Lorenzi L, Tabellini G, Vermi W, et al. Occurrence
of nodular lymphocyte-predominant Hodgkin
lymphoma in Hermansky-Pudlak type 2 syndrome
is associated to natural killer and natural killer
T cell defects. PLoS One. 2013;8(11):e80131.
14. Vieira PL, de Jong EC, Wierenga EA, Kapsenberg
ML, Kalin´ski P. Development of Th1-inducing
capacity in myeloid dendritic cells requires
environmental instruction. J Immunol. 2000;
164(9):4507-4512.
15. Fontana S, Moratto D, Mangal S, et al. Functional
defects of dendritic cells in patients with CD40
deficiency. Blood. 2003;102(12):4099-4106.
16. Del Prete A, Luganini A, Scutera S, et al.
Interferon-a production by plasmacytoid dendritic
cells is dispensable for an effective anti-
cytomegalovirus response in adaptor protein-3-
deficient mice. J Interferon Cytokine Res. 2015;
35(3):232-238.
17. Vallejo MO, Niemeyer GP, Vaglenov A, et al.
Decreased hematopoietic progenitor cell
mobilization in pearl mice. Exp Hematol. 2013;
41(10):848-857.
18. Swiecki M, Colonna M. The multifaceted biology
of plasmacytoid dendritic cells. Nat Rev Immunol.
2015;15(8):471-485.
19. Tourkova IL, Yurkovetsky ZR, Shurin MR,
Shurin GV. Mechanisms of dendritic cell-
induced T cell proliferation in the primary
MLR assay. Immunol Lett. 2001;78(2):
75-82.
20. Bromelow KV, Hirst W, Mendes RL, et al.
Whole blood assay for assessment of the
mixed lymphocyte reaction. J Immunol Methods.
2001;247(1-2):1-8.
3386 PRANDINI et al BLOOD, 30 JUNE 2016 x VOLUME 127, NUMBER 26
For personal use only.on August 7, 2016. by guest  www.bloodjournal.orgFrom 
online May 13, 2016
 originally publisheddoi:10.1182/blood-2015-06-650689
2016 127: 3382-3386
 
 
Facchetti, Silvano Sozzani and Raffaele Badolato
Maria Antonia De Francesco, Lucia Dora Notarangelo, Fulvio Porta, Alessandro Plebani, Fabio 
Alberto Prandini, Valentina Salvi, Francesca Colombo, Daniele Moratto, Luisa Lorenzi, William Vermi,
 
complex deficiency
Impairment of dendritic cell functions in patients with adaptor protein-3
 
http://www.bloodjournal.org/content/127/26/3382.full.html
Updated information and services can be found at:
 (5402 articles)Immunobiology    
 (1891 articles)Brief Reports    
Articles on similar topics can be found in the following Blood collections
http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests
Information about reproducing this article in parts or in its entirety may be found online at:
http://www.bloodjournal.org/site/misc/rights.xhtml#reprints
Information about ordering reprints may be found online at:
http://www.bloodjournal.org/site/subscriptions/index.xhtml
Information about subscriptions and ASH membership may be found online at:
  
Copyright 2011 by The American Society of Hematology; all rights reserved.
of Hematology, 2021 L St, NW, Suite 900, Washington DC 20036.
Blood (print ISSN 0006-4971, online ISSN 1528-0020), is published weekly by the American Society
For personal use only.on August 7, 2016. by guest  www.bloodjournal.orgFrom 
